Alexion preps an FDA pitch on Soliris successor while signaling more deals ahead for rare disease drugs
Alexion used its Q1 update Thursday to unveil another set of Phase III non-inferior stats for its Soliris successor, adding to its regulatory package for new approvals that should ship later this year.
Following earlier proof of non-inferiority for treatment-naive patients, the new Phase III highlighted their successful switching of Soliris patients to ALXN1210, a shift from dosing every two weeks to eight weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.